Ki Y. Chung
Expertise in
45
conditions

Dr. Ki Y. Chung

Oncology | Hematology Oncology
2400 Boiling Springs Road, 
Boiling Springs, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral required
Before you request
Expertise in
45
conditions
2400 Boiling Springs Road, 
Boiling Springs, SC 

Overview

Ki Chung is a Hematologist Oncology specialist and an Oncologist practicing medicine in Boiling Springs, South Carolina.

Dr. Chung is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Lung Cancer, and Anal Cancer.

Dr. Chung is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 18 peer reviewed articles and participating in 77 clinical trials. Dr. Chung is currently accepting new patients.

Graduate Institution

University Of North Carolina At Chapel Hill

Residency

Sinai Hospital-Baltimore

Specialties

Oncology
Hematology Oncology

Licenses

Internal Medicine in SC

Board Certifications

American Board Of Internal Medicine

Fellowships

Memorial Sloan-Kettering Cancer Center

Hospital Affiliations

Prisma Health Greer Memorial Hospital
Prisma Health Greenville Memorial Hospital
Prisma Health Patewood Hospital
Spartanburg Medical Center
Prisma Health Hillcrest Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Prisma Health Cancer Institute – Spartanburg
2400 Boiling Springs Road, Boiling Springs, SC 29316
Other Locations
Prisma Health Cancer Institute Multidisciplinary Center – Faris Rd.
890 West Faris Road, Suite 320, Greenville, SC 29605
Prisma Health Cancer Institute – Greer
340 Medical Parkway, Greer, SC 29650
Prisma Health Cancer Institute – Institute for Translational Oncology Research
900 West Faris Road, Greenville, SC 29605

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

77 Clinical Trials

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Other
Study Phase: Not Applicable
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Study Phase: Phase 2
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
View 9 Less Clinical Trials

18 Total Publications

Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Journal: JCO oncology advances
Published: April 29, 2026
Similar Doctors
Expertise in
76
conditions
Dr. Britt H. Bolemon
Oncology | Hematology Oncology
Expertise in
76
conditions
Dr. Britt H. Bolemon
Oncology | Hematology Oncology
Referral required
Before you request

Prisma Health Cancer Institute – Eastside

65 International Drive, 
Greenville, SC 
 (5.6 miles away)
864-987-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Britt Bolemon is a Hematologist Oncology specialist and an Oncologist practicing medicine in Greenville, South Carolina. Dr. Bolemon is highly rated in 76 conditions, according to our data. His clinical expertise encompasses Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Lung Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Bolemon is board certified in American Board Of Internal Medicine. Dr. Bolemon is currently accepting new patients.

Expertise in
40
conditions
Dr. Suzanne R. Fanning
Oncology | Hematology Oncology
Expertise in
40
conditions
Dr. Suzanne R. Fanning
Oncology | Hematology Oncology
Referral required
Before you request

Prisma Health Cancer Institute – Eastside

65 International Drive, 
Greenville, SC 
 (5.6 miles away)
864-987-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Suzanne Fanning is a Hematologist Oncology specialist and an Oncologist practicing medicine in Greenville, South Carolina. Dr. Fanning is highly rated in 40 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Fanning is board certified in American Board Of Internal Medicine. Dr. Fanning is currently accepting new patients.

Expertise in
23
conditions
Dr. Carla W. Jorgensen
Oncology | Hematology Oncology
Expertise in
23
conditions
Dr. Carla W. Jorgensen
Oncology | Hematology Oncology
Referral may be required
Before you request

Prisma Health Cancer Institute – Grove Commons

3 Butternut Drive, Suite B, 
Greenville, SC 
 (0.5 miles away)
864-241-7272
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carla Jorgensen is a Hematologist Oncology specialist and an Oncologist practicing medicine in Greenville, South Carolina. Dr. Jorgensen is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Lung Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Jorgensen is board certified in American Board Of Internal Medicine. Dr. Jorgensen is currently accepting new patients.

Frequently Asked Questions about Dr. Ki Y. Chung

How do I make an appointment with Dr. Ki Y. Chung?

You can book an appointment with Dr. Ki Y. Chung by calling their office at 864-599-0731. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ki Y. Chung a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ki Y. Chung is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ki Y. Chung specialize in?

While Dr. Ki Y. Chung is a Oncology, they have specific expertise in Colorectal Cancer, Familial Colorectal Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Ki Y. Chung participate in research or clinical trials?

Yes. Dr. Ki Y. Chung has published 18 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Ki Y. Chung's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ki Y. Chung accept my insurance?

Dr. Ki Y. Chung accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 864-599-0731 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chung's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 37 Advanced Conditions
    View All 113 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile